Abeona Therapeutics Inc (ABEO NASDAQ) stock market data APIs
$5.9051
0(0%)
as of July 15, 2025
Try our APIs with
free plan!
Abeona Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Prev. Close
5.9051
Open
5.9051
High
5.9858
Low
5.7837
52 wk Range
3.9328-7.3236
Market Cap
303 M
Shares Outstanding
51 157 K
EPS
-0.24
Beta
1.547
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abeona Therapeutics Inc data using free add-ons & libraries
Get Abeona Therapeutics Inc Fundamental Data
Abeona Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -67 561 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.354
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abeona Therapeutics Inc News
New
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
- Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a dec...
H.C. Wainwright maintains Buy rating on Abeona Therapeutics stock despite FDA setback
Investing.com - H.C. Wainwright has reiterated its Buy rating and $20.00 price target on Abeona Therapeutics (NASDAQ:ABEO), currently trading at $5.74 with a market cap of $294 million, following the ...
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (...
Abeona sells Rare Pediatric Disease PRV for $155M
[3D virus cells attacking a DNA strand] fatido/E+ via Getty Images * Shares of Abeona Therapeutics (NASDAQ:ABEO [https://seekingalpha.com/symbol/ABEO]) rose on Wednesday after the company said that...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
